Symphogen Launches New Website and Marketing Materials
Complete the form below to unlock access to ALL audio articles.
Symphogen has recently launched a new website accompanied by several new factsheets detailing the company, technology and products.
Symphogen’s recombinant polyclonal antibody products are geared to the treatment of diseases caused by complex target antigens such as cancer, infectious diseases, transplantation rejection, and allergy.
The Company’s lead product, which combines 25 different recombinant anti-Rhesus D (RhD) antibodies for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN), is expected to enter the clinic in 2006.